Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: An analysis of the Scientific Registry of Transplant Recipients Database

Liver Transplantation

Volumn 18, Issue 9, 2012, Pages 1029-1036

  Watt, Kymberly D ^a   Dierkhising, Ross ^b   Heimbach, Julie K ^a   Charlton, Michael R ^a  

^a MAYO CLINIC   (United States)

^b Division of Biomedical Statistics and Informatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN; RAPAMYCIN; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ARTICLE; CREATININE BLOOD LEVEL; DATA BASE; DIABETES MELLITUS; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN DONOR; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT;

ADULT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TACROLIMUS; TIME FACTORS;

EID: 84865593597     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23479     Document Type: Article

References (25)

1. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA,. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896. (Pubitemid 34267271)
3. Wiesner RH,. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493-499. (Pubitemid 28415377)
4. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450. (Pubitemid 32492583)
5. Berenguer M,. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8 (suppl 1): S14-S18. (Pubitemid 35154038)
6. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120-1130. (Pubitemid 39248409)
7. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240-1247. (Pubitemid 39406077)
8. Prieto M, Berenguer M, Rayõn JM, Cõrdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-256. (Pubitemid 29024010)
9. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820. (Pubitemid 26099603)
10. Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006; 12: 1640-1648. (Pubitemid 44742543)
11. Wiesner R, Klintmalm G, McDiarmid S,; for Rapamune Liver Transplant Study Group. Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients [abstract]. Am J Transplant 2002; 2 (suppl 3): 464.
12. Wagner D, Kniepeiss D, Schaffellner S, Jakoby E, Mueller H, Fahrleitner-Pammer A, et al. Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates. Int Immunopharmacol 2010; 10: 990-993.
13. Asthana S, Toso C, Meeberg G, Bigam DL, Mason A, Shapiro J, Kneteman NM,. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011; 25: 28-34.
14. De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E, et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 2009; 22: 279-286.
15. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J,. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45: 786-796. (Pubitemid 44646687)
16. Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F,. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011; 55: 388-398.
17. Ishida H, Li K, Yi M, Lemon SM,. p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. J Biol Chem 2007; 282: 11836-11848. (Pubitemid 47100711)
18. Mannová P, Beretta L,. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol 2005; 79: 8742-8749. (Pubitemid 40934785)
19. Shao RX, Zhang L, Peng LF, Sun E, Chung WJ, Jang JY, et al. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner. J Virol 2010; 84: 6060-6069.
20. Matsumoto A, Ichikawa T, Nakao K, Miyaaki H, Hirano K, Fujimito M, et al. Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. J Gastroenterol 2009; 44: 856-863.
21. Kaur S, Lal L, Sassano A, Majchrzak-Kita B, Srikanth M, Baker DP, et al. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 2007; 282: 1757-1768. (Pubitemid 47076718)
22. Su WC, Liu WL, Cheng CW, Chou YB, Hung KH, Huang WH, et al. Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. FEBS Lett 2009; 583: 2793-2798.
23. Irish WD, Arcona S, Bowers D, Trotter JF,. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011; 11: 1676-1685.
24. Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A,. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant 2010; 10: 590-601.
25. A comparison of tacrolimus (FK,506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331: 1110-1115.